New York Budget Proposal May Reduce Biomarker Testing Coverage for Medicaid
New York state is considering a budget proposal that could potentially reduce access to biomarker testing for Medicaid recipients. Biomarker testing has been recognized as a significant advancement in cancer care, providing personalized treatment options based on individual genetic markers. Three years ago, New York expanded access to this testing, marking a progressive step in healthcare. However, advocates are now concerned that the proposed budget could reverse these advancements, limiting the availability of biomarker testing for those on Medicaid. This development has sparked debate among healthcare advocates who emphasize the importance of maintaining access to such critical diagnostic tools.